By Chelsea Naso ( August 7, 2017, 5:49 PM EDT) -- New York-based Acorda Therapeutics on Monday fired back against a hedge fund's calls for the biopharmaceutical company to sell itself, contending that more value can be derived from focusing on its late-stage Parkinson's disease therapies and appealing a patent ruling concerning a multiple sclerosis drug....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.